Biopharmaceutical firms in China are focusing on the development of new COVID-19 treatments, designed to tackle new Omicron variants.
While much of the developed world has moved on from the acute phase of the coronavirus pandemic, China has to some extent been a victim of its own success in stopping the initial waves of infection.
As a result, the country is believed to have relatively low levels of natural immunity, while homegrown vaccines such as CanSino Biologics’ (SSE: 688185) Convidecia do not have the same level of efficacy as mRNA-based jabs developed abroad.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze